Pyxis Oncology (NASDAQ:PYXS – Get Free Report) is projected to release its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect Pyxis Oncology to announce earnings of ($0.27) per share for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 6, 2026 at 9:30 AM ET.
Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.05). On average, analysts expect Pyxis Oncology to post ($1.21) EPS for the current fiscal year and ($1.10) EPS for the next fiscal year.
Pyxis Oncology Stock Performance
PYXS opened at $1.81 on Friday. Pyxis Oncology has a fifty-two week low of $1.03 and a fifty-two week high of $5.55. The firm’s fifty day moving average is $2.66 and its 200 day moving average is $2.16.
Wall Street Analyst Weigh In
A number of research firms have commented on PYXS. Wells Fargo & Company raised their price target on Pyxis Oncology from $12.00 to $19.00 and gave the company an “overweight” rating in a report on Wednesday, September 9th. Wedbush boosted their price objective on Pyxis Oncology from $6.00 to $8.00 and gave the company an “outperform” rating in a research report on Thursday, September 10th. HC Wainwright upped their price objective on Pyxis Oncology from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Pyxis Oncology in a research report on Friday, September 25th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $8.75.
View Our Latest Report on PYXS
About Pyxis Oncology
Pyxis Oncology, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for the treatment of cancer. The company aims to address limitations of existing cancer treatments by designing therapeutics intended to selectively target tumors and activate the immune system while minimizing effects on healthy tissue.
Pyxis Oncology’s pipeline includes antibody-drug conjugates and immunotherapies designed to act on targets in the tumor microenvironment. Its lead programs have included PYX-201, an antibody-drug conjugate intended to deliver a cytotoxic payload to tumors expressing the fibronectin extra domain-B target, and other investigational antibody-based programs directed at immune-suppressive pathways.
Read More
- Five stocks we like better than Pyxis Oncology
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
